Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United States.

Wu, Yanyu; Sun, Shawn X; Fan, Tao

Wu, Yanyu; Sun, Shawn X; Fan, Tao.

Afiliación

Wu Y; Global Evidence & Outcomes, Data Sciences Institute, Research and Development, Takeda Development Center Americas, Inc, Cambridge, MA, USA.
Sun SX; Global Evidence & Outcomes, Data Sciences Institute, Research and Development, Takeda Development Center Americas, Inc, Cambridge, MA, USA.
Fan T; US Health Economics and Outcomes Research, Takeda Pharmaceuticals USA, Inc, Lexington, MA, USA.

J Blood Med ; 13: 517-524, 2022.

Article en En | MEDLINE | ID: mdl-36188439

Palabras clave

PEGylated; antihemophilic factor (recombinant); dosing patterns; efmoroctocog alfa; fragment crystallizable fusion protein; hemophilia A; rurioctocog alfa pegol

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: J Blood Med Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google